Agilent to Acquire GenDx for $217 Million

TL;DR

Agilent buying GenDx for $217M to boost diagnostics biz.

AI Summary

Agilent Technologies, Inc. announced on September 4, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of GenDx for approximately $217 million. GenDx is a Dutch company specializing in molecular diagnostic solutions for transplantation and infectious diseases. The acquisition is expected to close in the fourth quarter of Agilent's fiscal year 2024.

Why It Matters

This acquisition expands Agilent's presence in the growing field of molecular diagnostics, particularly in transplantation, which could lead to increased revenue and market share in this specialized area.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which introduces some uncertainty regarding the completion and timing of the deal.

Key Numbers

• $217 million — Acquisition Price (Total cost to acquire GenDx)

Key Players & Entities

• Agilent Technologies, Inc. (company) — Acquiring company
• GenDx (company) — Target company
• $217 million (dollar_amount) — Acquisition price
• September 4, 2024 (date) — Date of agreement
• fourth quarter of fiscal year 2024 (date) — Expected closing period

FAQ

From the Filing

0001193125-24-214337.txt : 20240905 0001193125-24-214337.hdr.sgml : 20240905 20240905172800 ACCESSION NUMBER: 0001193125-24-214337 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240904 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILENT TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001090872 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 770518772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15405 FILM NUMBER: 241282300 BUSINESS ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: (408) 345-8886 MAIL ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD, MS 1A-LC STREET 2: P.O. BOX 58059 CITY: SANTA CLARA STATE: CA ZIP: 95052-8059 FORMER COMPANY: FORMER CONFORMED NAME: AGILENT TECHNOLOGIES INC DATE OF NAME CHANGE: 19990816 FORMER COMPANY: FORMER CONFORMED NAME: HP MEASUREMENT INC DATE OF NAME CHANGE: 19990716 8-K 1 d891217d8k.htm 8-K 8-K 0001090872 false 0001090872 2024-09-04 2024-09-04     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024     AGILENT TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter)       Delaware   001-15405   77-0518772 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   5301 Stevens Creek Boulevard , Santa Clara , CA   95051 (Address of Principal Executive Offices)   (Zip Code) Registrant’s telephone number, including area code ( 800 ) 227-9770   (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   A   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)  ☐ . If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01. Other Events. On September 4, 2024, Agilent Technologies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Und